查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2085407

咳嗽敏感症候群治療市場：按劑型、作用機制、處方類型、患者年齡層和最終用戶分類－2026-2032年全球市場預測

Cough Hypersensitivity Syndrome Treatment Market by Formulation, Mechanism of Action, Prescription Type, Patient Age Group, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，咳嗽刺激症候群治療市場規模將成長至 169.1 億美元，複合年成長率為 7.17%。

主要市場統計數據
基準年 2025 104.1億美元
預計年份：2026年 110.3億美元
預測年份：2032年 169.1億美元
複合年成長率 (%) 7.17%

咳嗽過敏症候群 (CVS) 的治療正從廣泛的症狀控制轉向針對病因的治療，尤其針對持續超過八週的慢性咳嗽患者。此疾病的特徵是氣道感覺神經過敏，常由冷空氣、說話、氣味、逆流、氣喘、上呼吸道疾病或病毒感染等因素誘發。經過同行評審的流行病學研究一​​致表明，慢性咳嗽影響著全球約十分之一的成年人，因此，準確診斷、針對咳嗽的特異性治療以及慢性咳嗽的多學科管理仍然至關重要。

臨床上對難治性慢性咳嗽和不明原因慢性咳嗽的需求最高，這些病例的症狀無法透過氣喘、鼻炎和胃食道逆流的常規治療完全緩解。咳嗽專科診所、檢驗的咳嗽嚴重程度評估量表、基於言語治療的咳嗽控制療法、神經調節劑以及旨在改善患者自述生活品質 (QOL) 並抑制病理性咳嗽反射訊號的新型 P2X3 受體拮抗劑，都支撐著市場趨勢。

治療前景的變革性變化

隨著我們對神經發炎、迷走神經傳入活化、喉部高敏感性以及可治療特徵的理解不斷加深，咳嗽過敏症候群的治療方法正在被重新定義。傳統上，慢性咳嗽的治療主要依賴於針對常見原因的經驗性治療。而目前的臨床實踐越來越注重區分難治性慢性咳嗽和疾病特異性咳嗽，從而更好地篩選適合接受行為療法、神經調節劑治療以及標靶藥物研發的患者。

人工智慧（AI）的累積影響

人工智慧（AI）正逐漸成為咳嗽刺激症候群整體治療中累積的驅動力，尤其是在數位咳嗽監測、表現型檢測和臨床試驗設計方面。 AI驅動的聲學演算法能夠客觀地量化咳嗽頻率，從而減少對患者記憶的依賴，並提高分佈式、混合式和真實世界證據研究中測量結果的一致性。

關鍵區域洞察

北美憑藉其先進的呼吸科、過敏科、耳鼻喉科和胃腸病科服務、完善的臨床實驗室基礎設施以及學術機構中日益普及的客觀咳嗽評估方法，仍然是咳嗽過敏症候群治療研究領域的主導地區。美國透過其專家網路和臨床研究活動推動了大部分創新，而加拿大則透過循證慢性咳嗽治療方案和全面呼吸護理做出貢獻。

關鍵群體特定見解

從群體層面的需求模式來看，我們發現咳嗽過敏症候群治療藥物的引入促進因素各不相同。七國集團（G7）國家由於其高額的醫療保健支出、專業的呼吸系統醫療網路、臨床試驗參與度以及完善的醫保報銷評估體系，在短期商業化方面準備最為充分。北約成員國與高所得的北美和歐洲市場高度重合，這些市場普遍採用臨床指南、藥物安全監測系統以及向專家傳播訊息的管道，這些都為新型止咳藥的系統性引入提供了支持。

主要國家的關鍵見解

美國是治療咳嗽過敏症候群的領先創新中心，這得益於生物製藥研究、呼吸科專家、咳嗽相關臨床試驗以及數位醫療的應用，儘管針對P2X3的藥物核准趨勢仍需密切關注。加拿大正在採用循證呼吸系統護理路徑和綜合護理模式，而隨著人們對慢性咳嗽作為一種可治療的神經感覺症候群的認知不斷提高，墨西哥和巴西的治療機會也在增加。

為行業領導者提供的實用建議

產業領導者應優先考慮咳嗽過敏症候群治療中差異化的療效、耐受性和真實世界臨床價值。與第一代P2X3療法相比，新一代療法應能顯著降低咳嗽頻率，改善咳嗽患者的生活品質，具有持久療效，並具有更佳的味覺耐受性。研發項目應根據患者類型進行分層，例如難治性慢性咳嗽、病因不明的慢性咳嗽、氣喘相關性咳嗽、逆流相關性咳嗽、上呼吸道咳嗽症候群和病毒感染後咳嗽，以提高治療反應的可預測性。

調查方法

本調查方法整合了二手研究、臨床指南審查、監管資訊、流行病學分析和定性市場三角測量。資訊來源包括同行評審的呼吸系統、過敏、胃腸病學和耳鼻喉科文獻、關於慢性咳嗽的共識聲明、臨床實驗室註冊資訊、已通過核准的產品附加檔、已發布的監管文件、醫療保健使用資料集以及公開的行業披露資訊。

結論

隨著臨床醫生、監管機構和藥物研發人員日益認知到慢性咳嗽不僅是潛在疾病的症狀，更是一種神經感覺障礙，咳嗽過敏症候群的治療正朝著更有針對性的方向發展。最大的機會在於難治性和不明原因的慢性咳嗽領域，該領域仍存在大量未被滿足的需求，且臨床文獻已充分證實其會導致患者生活品質下降。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 工業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章 咳嗽過敏症候群治療市場：依劑型分類

  • 吸入
    • 乾粉吸入器
    • 定量噴霧吸入器
  • 噴霧器
  • 口服
    • 膠囊
    • 藥片
  • 糖漿

第8章：咳嗽過敏症候群治療市場：依作用機轉分類

  • 感覺神經調節
  • 中樞神經系統抑制
  • 抗發炎作用
  • 支氣管擴張

第9章：咳嗽過敏症候群治療市場：依處方類型分類

  • 非處方藥
  • 複方藥物

第10章：咳嗽過敏症候群治療市場：依患者年齡層分類

  • 成人
  • 老年人
  • 兒童

第11章：咳嗽敏感症候群治療市場：依最終用戶分類

  • 居家醫療
  • 醫院
    • 綜合醫院
    • 專科醫院
  • 專科診所
    • 耳鼻喉科診所
    • 呼吸系統醫療設備

第12章 咳嗽過敏症候群治療市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第13章：咳嗽過敏症候群治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章：咳嗽過敏症候群治療市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第16章：公司簡介

  • AstraZeneca PLC
  • Bayer AG
  • Bellus Health Inc.
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Evommune, Inc.
  • Evotec SE
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline plc
  • Haleon plc
  • Johnson & Johnson Service Inc.
  • Kyorin Pharmaceutical Co., Ltd.
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Procter & Gamble Company
  • Reckitt Benckiser Group plc
  • Sanofi SA
  • Shanghai Hengrui Pharmaceuticals Co., Ltd.
  • Shionogi & Co., Ltd.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • Trevi Therapeutics, Inc.
  • Vertex Pharmaceuticals Incorporated
  • Viatris Inc.
  • Zambon SpA
Product Code: MRR-4311CE1A33E2

The Cough Hypersensitivity Syndrome Treatment Market is projected to grow by USD 16.91 billion at a CAGR of 7.17% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 10.41 billion
Estimated Year [2026] USD 11.03 billion
Forecast Year [2032] USD 16.91 billion
CAGR (%) 7.17%

Cough hypersensitivity syndrome treatment is moving from broad symptom suppression toward mechanism-led care for patients with chronic cough lasting more than eight weeks. The condition is characterized by heightened sensitivity of airway sensory nerves, often triggered by cold air, talking, odors, reflux, asthma, upper-airway disease, or viral injury. Peer-reviewed epidemiology studies consistently indicate that chronic cough affects approximately one in ten adults globally, creating sustained need for accurate diagnosis, cough-specific therapies, and multidisciplinary chronic cough management.

Clinical demand is strongest in refractory chronic cough and unexplained chronic cough, where conventional therapies for asthma, rhinitis, and gastroesophageal reflux disease do not fully resolve symptoms. Market activity is supported by specialty cough clinics, validated cough severity instruments, speech pathology-based cough control therapy, neuromodulators, and emerging P2X3 receptor antagonists designed to reduce pathologic cough reflex signaling while improving patient-reported quality of life.

Transformative Shifts in the Treatment Landscape

The cough hypersensitivity syndrome treatment landscape is being reshaped by clearer understanding of neuroinflammation, vagal afferent nerve activation, laryngeal hypersensitivity, and treatable traits. Historically, chronic cough care depended heavily on empirical therapy for common causes. Current practice increasingly differentiates refractory chronic cough from disease-specific cough, improving patient selection for behavioral therapy, neuromodulators, and targeted drug development.

A major shift is the rise of P2X3 antagonism, supported by regulatory approvals of gefapixant in markets including Japan, the European Union, and Switzerland for refractory or unexplained chronic cough. At the same time, regulators have placed high emphasis on clinically meaningful efficacy, taste-related tolerability, safety, and patient-reported outcomes. This is encouraging next-generation selective P2X3 programs and non-opioid antitussive strategies with improved benefit-risk profiles.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is becoming a cumulative enabler across cough hypersensitivity syndrome treatment, particularly in digital cough monitoring, phenotype discovery, and clinical trial design. AI-enabled acoustic algorithms can quantify cough frequency objectively, helping reduce reliance on patient recall and improving measurement consistency in decentralized, hybrid, and real-world evidence studies.

In clinical development, machine learning can integrate spirometry, eosinophil markers, reflux history, medication exposure, voice and cough acoustics, and quality-of-life scores to identify responsive subgroups. In care delivery, AI-supported triage tools can help clinicians distinguish red-flag cough from chronic refractory cough pathways, while validation, privacy protection, interoperability, and bias monitoring remain essential for safe deployment.

Key Regional Insights

North America remains a leading region for cough hypersensitivity syndrome treatment research due to advanced pulmonary, allergy, otolaryngology, and gastroenterology care, strong clinical trial infrastructure, and growing use of objective cough assessment in academic centers. The United States drives much of the innovation pipeline through specialist networks and clinical research activity, while Canada contributes through evidence-based chronic cough pathways and integrated respiratory care.

Europe shows strong uptake potential because the European Union has authorized gefapixant for adults with refractory or unexplained chronic cough, supporting physician familiarity with targeted therapy and structured pharmacovigilance. Asia-Pacific is highly significant, with Japan among the earliest countries to approve a P2X3 antagonist and China, India, South Korea, and Australia expanding specialty respiratory services, digital health adoption, and clinical evidence generation. Latin America is gaining attention as chronic respiratory disease burden and access to specialist care increase, while the Middle East is supported by investment in advanced hospitals and digital health systems. Africa presents longer-term opportunity tied to respiratory diagnostic capacity, specialist availability, affordability, and broader access to chronic disease management.

Key Group Insights

Group-level demand patterns show different adoption drivers across cough hypersensitivity syndrome treatment. The G7 countries have the strongest near-term commercialization readiness because of high healthcare spending, specialized respiratory networks, clinical trial participation, and established reimbursement evaluation systems. NATO countries overlap substantially with high-income North American and European markets, where clinical guideline adoption, pharmacovigilance systems, and specialist referral pathways support structured introduction of novel antitussives.

The European Union is important because centralized and national regulatory processes create a defined pathway for targeted chronic cough therapies, supported by health technology assessment and post-authorization safety monitoring. BRICS countries offer scale, with China and India anchoring large patient pools and rising access to specialty diagnostics, while Brazil, Russia, and South Africa show variable adoption influenced by reimbursement, infrastructure, and respiratory care capacity. ASEAN markets are developing through urban hospital networks, private respiratory care, and digital health expansion, while GCC countries benefit from investment in specialty clinics, tertiary hospitals, and healthcare modernization programs.

Key Country Insights

The United States is the largest innovation hub for cough hypersensitivity syndrome treatment, supported by biopharmaceutical research, pulmonary specialists, cough-related clinical trial activity, and digital health adoption, although targeted P2X3 approval dynamics remain closely watched. Canada follows evidence-based respiratory pathways and integrated care models, while Mexico and Brazil present expanding access opportunities as awareness of chronic cough as a treatable neuro-sensory syndrome improves.

In Europe, the United Kingdom, Germany, France, Italy, and Spain are positioned for structured adoption through specialist referral networks, respiratory societies, and health technology assessment, while Russia faces more variable access conditions due to differences in reimbursement and care delivery. China and India represent high-volume markets where diagnosis, affordability, specialist distribution, and reimbursement will shape uptake. Japan leads in early targeted therapy experience following P2X3 antagonist approval, South Korea shows strong specialist readiness and digital health capacity, and Australia supports high-quality clinical evidence generation through established respiratory research networks and guideline-based chronic cough care.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize differentiated efficacy, tolerability, and real-world value in cough hypersensitivity syndrome treatment. Next-generation therapies need to demonstrate meaningful reductions in objective cough frequency, improved cough-specific quality of life, durable benefit, and better taste tolerability than first-generation P2X3 approaches. Development programs should stratify patients by refractory chronic cough, unexplained chronic cough, asthma-related cough, reflux-associated cough, upper-airway cough syndrome, and post-viral cough to improve response predictability.

Commercial and medical teams should invest in physician education, referral pathways, patient identification, and digital cough monitoring partnerships. Payers will expect clear evidence of reduced healthcare utilization, sleep disruption, productivity loss, unnecessary antibiotic use, and avoidable steroid exposure. Organizations that combine pharmacologic treatment with behavioral cough suppression therapy, objective monitoring, and validated patient-reported outcomes will be better positioned for durable adoption.

Research Methodology

The research methodology integrates secondary research, clinical guideline review, regulatory intelligence, epidemiology analysis, and qualitative market triangulation. Sources include peer-reviewed respiratory, allergy, gastroenterology, and otolaryngology literature; chronic cough consensus statements; clinical trial registries; approved product labels; public regulatory documents; healthcare utilization datasets; and publicly available industry disclosures.

Insights are validated through cross-comparison of disease prevalence, treatment algorithms, approval status, reimbursement signals, patient-reported outcome evidence, and regional access patterns. The methodology emphasizes verified evidence over speculative market sizing, with qualitative assessment of pipeline innovation, patient segmentation, unmet need, safety considerations, and adoption barriers across regions, groups, and key countries.

Conclusion

Cough hypersensitivity syndrome treatment is entering a more targeted era as clinicians, regulators, and drug developers increasingly recognize chronic cough as a neuro-sensory disorder rather than only a symptom of underlying disease. The strongest opportunities are in refractory and unexplained chronic cough, where unmet need remains high and quality-of-life impairment is well documented in clinical literature.

Future leadership will depend on therapies that combine measurable cough reduction, tolerability, durable patient benefit, and payer-relevant outcomes. With growing use of AI-based cough monitoring, specialty referral pathways, behavioral cough suppression therapy, and mechanism-based drug development, the sector is positioned for continued advancement in precision respiratory care.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Cough Hypersensitivity Syndrome Treatment Market, by Formulation

  • 7.1. Inhalation
    • 7.1.1. Dry Powder Inhaler
    • 7.1.2. Metered Dose Inhaler
  • 7.2. Nebulizer
  • 7.3. Oral
    • 7.3.1. Capsule
    • 7.3.2. Tablet
  • 7.4. Syrup

8. Cough Hypersensitivity Syndrome Treatment Market, by Mechanism of Action

  • 8.1. Sensory Nerve Modulation
  • 8.2. Central Nervous System Suppression
  • 8.3. Anti-inflammatory Action
  • 8.4. Bronchodilation

9. Cough Hypersensitivity Syndrome Treatment Market, by Prescription Type

  • 9.1. Over The Counter
  • 9.2. Prescription

10. Cough Hypersensitivity Syndrome Treatment Market, by Patient Age Group

  • 10.1. Adults
  • 10.2. Geriatrics
  • 10.3. Pediatrics

11. Cough Hypersensitivity Syndrome Treatment Market, by End User

  • 11.1. Home Care Settings
  • 11.2. Hospitals
    • 11.2.1. General Hospitals
    • 11.2.2. Specialty Hospitals
  • 11.3. Specialty Clinics
    • 11.3.1. Ent Clinics
    • 11.3.2. Pulmonology Clinics

12. Cough Hypersensitivity Syndrome Treatment Market, by Region

  • 12.1. Asia-Pacific
  • 12.2. North America
  • 12.3. Latin America
  • 12.4. Europe
  • 12.5. Middle East
  • 12.6. Africa

13. Cough Hypersensitivity Syndrome Treatment Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Cough Hypersensitivity Syndrome Treatment Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Concentration Analysis, 2025
    • 15.1.1. Concentration Ratio (CR)
    • 15.1.2. Herfindahl Hirschman Index (HHI)
  • 15.2. Recent Developments & Impact Analysis, 2025
  • 15.3. Product Portfolio Analysis, 2025
  • 15.4. Benchmarking Analysis, 2025

16. Company Profiles

  • 16.1. AstraZeneca PLC
  • 16.2. Bayer AG
  • 16.3. Bellus Health Inc.
  • 16.4. Boehringer Ingelheim International GmbH
  • 16.5. Bristol-Myers Squibb Company
  • 16.6. Evommune, Inc.
  • 16.7. Evotec SE
  • 16.8. F. Hoffmann-La Roche AG
  • 16.9. GlaxoSmithKline plc
  • 16.10. Haleon plc
  • 16.11. Johnson & Johnson Service Inc.
  • 16.12. Kyorin Pharmaceutical Co., Ltd.
  • 16.13. Merck & Co., Inc.
  • 16.14. Novartis AG
  • 16.15. Pfizer Inc.
  • 16.16. Procter & Gamble Company
  • 16.17. Reckitt Benckiser Group plc
  • 16.18. Sanofi S.A.
  • 16.19. Shanghai Hengrui Pharmaceuticals Co., Ltd.
  • 16.20. Shionogi & Co., Ltd.
  • 16.21. Takeda Pharmaceutical Company Limited
  • 16.22. Teva Pharmaceutical Industries Ltd.
  • 16.23. Trevi Therapeutics, Inc.
  • 16.24. Vertex Pharmaceuticals Incorporated
  • 16.25. Viatris Inc.
  • 16.26. Zambon S.p.A.

LIST OF FIGURES

  • FIGURE 1. GLOBAL COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY FORMULATION, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY FORMULATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY MECHANISM OF ACTION, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY MECHANISM OF ACTION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY PRESCRIPTION TYPE, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY PRESCRIPTION TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL INHALATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL INHALATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL INHALATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL DRY POWDER INHALER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL DRY POWDER INHALER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL DRY POWDER INHALER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL METERED DOSE INHALER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL METERED DOSE INHALER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL METERED DOSE INHALER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL NEBULIZER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL NEBULIZER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL NEBULIZER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ORAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ORAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CAPSULE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CAPSULE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CAPSULE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL TABLET MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL TABLET MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL TABLET MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL SYRUP MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL SYRUP MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL SYRUP MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL SENSORY NERVE MODULATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL SENSORY NERVE MODULATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL SENSORY NERVE MODULATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CENTRAL NERVOUS SYSTEM SUPPRESSION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CENTRAL NERVOUS SYSTEM SUPPRESSION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CENTRAL NERVOUS SYSTEM SUPPRESSION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ANTI-INFLAMMATORY ACTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ANTI-INFLAMMATORY ACTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ANTI-INFLAMMATORY ACTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL BRONCHODILATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL BRONCHODILATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL BRONCHODILATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL OVER THE COUNTER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL OVER THE COUNTER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL OVER THE COUNTER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL PRESCRIPTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL PRESCRIPTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL PRESCRIPTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ADULTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ADULTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ADULTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL GERIATRICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL GERIATRICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL GERIATRICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL PEDIATRICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL PEDIATRICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL PEDIATRICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL HOME CARE SETTINGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL HOME CARE SETTINGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL HOME CARE SETTINGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL GENERAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL GENERAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL GENERAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL SPECIALTY HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL SPECIALTY HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL SPECIALTY HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL ENT CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL ENT CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL ENT CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL PULMONOLOGY CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL PULMONOLOGY CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL PULMONOLOGY CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. ASIA-PACIFIC COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 81. ASIA-PACIFIC COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 82. ASIA-PACIFIC COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 83. ASIA-PACIFIC COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 84. ASIA-PACIFIC COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 85. ASIA-PACIFIC COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 86. ASIA-PACIFIC COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. ASIA-PACIFIC COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 88. ASIA-PACIFIC COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 89. ASIA-PACIFIC COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 90. NORTH AMERICA COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 92. NORTH AMERICA COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 93. NORTH AMERICA COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 94. NORTH AMERICA COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 95. NORTH AMERICA COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 96. NORTH AMERICA COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 98. NORTH AMERICA COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 99. NORTH AMERICA COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 100. LATIN AMERICA COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 101. LATIN AMERICA COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 102. LATIN AMERICA COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 103. LATIN AMERICA COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 104. LATIN AMERICA COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 105. LATIN AMERICA COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 106. LATIN AMERICA COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 107. LATIN AMERICA COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 108. LATIN AMERICA COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 109. LATIN AMERICA COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 120. MIDDLE EAST COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 121. MIDDLE EAST COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 122. MIDDLE EAST COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 123. MIDDLE EAST COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 124. MIDDLE EAST COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 125. MIDDLE EAST COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 126. MIDDLE EAST COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 127. MIDDLE EAST COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 128. MIDDLE EAST COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 129. MIDDLE EAST COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 130. AFRICA COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 131. AFRICA COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 132. AFRICA COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 133. AFRICA COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 134. AFRICA COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 135. AFRICA COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. AFRICA COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 137. AFRICA COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 138. AFRICA COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 139. AFRICA COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 141. ASEAN COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 142. ASEAN COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 143. ASEAN COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 144. ASEAN COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 145. ASEAN COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 146. ASEAN COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 147. ASEAN COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 148. ASEAN COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 149. ASEAN COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 150. ASEAN COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 151. GCC COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 152. GCC COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 153. GCC COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 154. GCC COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 155. GCC COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 156. GCC COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. GCC COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 158. GCC COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 159. GCC COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 160. GCC COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPEAN UNION COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPEAN UNION COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPEAN UNION COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPEAN UNION COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPEAN UNION COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPEAN UNION COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPEAN UNION COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPEAN UNION COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPEAN UNION COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPEAN UNION COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 171. BRICS COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 172. BRICS COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 173. BRICS COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 174. BRICS COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 175. BRICS COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 176. BRICS COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 177. BRICS COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 178. BRICS COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 179. BRICS COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 180. BRICS COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 181. G7 COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 182. G7 COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 183. G7 COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 184. G7 COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 185. G7 COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 186. G7 COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 187. G7 COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 188. G7 COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 189. G7 COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 190. G7 COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 191. NATO COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 192. NATO COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 193. NATO COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 194. NATO COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 195. NATO COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 196. NATO COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 197. NATO COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 198. NATO COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 199. NATO COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 200. NATO COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 201. GLOBAL COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 202. UNITED STATES COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 203. UNITED STATES COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 204. UNITED STATES COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 205. UNITED STATES COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 206. UNITED STATES COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 207. UNITED STATES COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 208. UNITED STATES COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 209. UNITED STATES COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 210. UNITED STATES COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 211. UNITED STATES COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 212. CANADA COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 213. CANADA COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 214. CANADA COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 215. CANADA COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 216. CANADA COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 217. CANADA COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 218. CANADA COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 219. CANADA COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 220. CANADA COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 221. CANADA COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 222. MEXICO COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 223. MEXICO COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 224. MEXICO COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 225. MEXICO COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 226. MEXICO COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 227. MEXICO COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 228. MEXICO COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 229. MEXICO COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 230. MEXICO COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 231. MEXICO COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 232. BRAZIL COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 233. BRAZIL COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 234. BRAZIL COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 235. BRAZIL COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 236. BRAZIL COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 237. BRAZIL COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 238. BRAZIL COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 239. BRAZIL COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 240. BRAZIL COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 241. BRAZIL COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 242. UNITED KINGDOM COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 243. UNITED KINGDOM COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 244. UNITED KINGDOM COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 245. UNITED KINGDOM COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 246. UNITED KINGDOM COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 247. UNITED KINGDOM COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 248. UNITED KINGDOM COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 249. UNITED KINGDOM COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 250. UNITED KINGDOM COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 251. UNITED KINGDOM COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 252. GERMANY COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 253. GERMANY COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 254. GERMANY COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 255. GERMANY COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 256. GERMANY COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 257. GERMANY COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 258. GERMANY COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 259. GERMANY COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 260. GERMANY COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 261. GERMANY COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 262. FRANCE COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 263. FRANCE COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 264. FRANCE COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 265. FRANCE COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 266. FRANCE COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 267. FRANCE COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 268. FRANCE COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 269. FRANCE COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 270. FRANCE COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 271. FRANCE COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 272. RUSSIA COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 273. RUSSIA COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 274. RUSSIA COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 275. RUSSIA COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 276. RUSSIA COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 277. RUSSIA COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 278. RUSSIA COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 279. RUSSIA COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 280. RUSSIA COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 281. RUSSIA COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 282. ITALY COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 283. ITALY COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 284. ITALY COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 285. ITALY COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 286. ITALY COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 287. ITALY COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 288. ITALY COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 289. ITALY COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 290. ITALY COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 291. ITALY COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 292. SPAIN COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 293. SPAIN COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 294. SPAIN COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 295. SPAIN COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 296. SPAIN COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 297. SPAIN COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 298. SPAIN COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 299. SPAIN COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 300. SPAIN COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 301. SPAIN COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 302. CHINA COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 303. CHINA COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 304. CHINA COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 305. CHINA COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 306. CHINA COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 307. CHINA COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 308. CHINA COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 309. CHINA COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-20